Biotechnology News

WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic,...

美國麻塞諸塞州沃爾瑟姆, Oct. 29, 2026 (GLOBE NEWSWIRE) --...

美国马萨诸塞州沃尔瑟姆, Oct. 29, 2026 (GLOBE NEWSWIRE) --...

KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b...

Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's diseaseLecanemab...

Biosplice executives discuss the need for innovation in knee osteoarthritis with Dr. Drew on Health Uncensored on Sunday, November 1st at 5:30pm.

Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis.

ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline

TME Pharma signs exclusive agreement with TMS Co. for NOX-A12, targeting ~€10M upfront/near-term cash & shares for worldwide rights.

TME Pharma signe avec TMS Co. pour NOX-A12 (~10 M€ d'acomptes/paiements initiaux en cash et actions) pour les droits mondiaux.